Navigation Links
Vermillion Reports First Quarter 2013 Results
Date:5/15/2013

A1 with current clinical practice and showing how OVA1 can greatly reduce the percentage of women who receive substandard care.  

The funding will also support two important strategic initiatives:

  • The company will migrate OVA1 to a state-of-the-art clinical testing platform commonly available around the world.  This will expand the market for the test to more laboratories and hospitals and enable licensing OVA1 in non-U.S. markets. It will require the successful execution of validation and clinical studies to support submission of a 510-K and FDA clearance. The company targets launch on this new platform by the end of 2014.
  • The company will also use the funding to accelerate the development of a next generation ovarian cancer diagnostic. This test will utilize a combination of current and novel biomarkers in a new algorithm to increase specificity and positive predictive value, while significantly reducing false positives. The company expects to announce proof of concept results during the second quarter and targets the launch of a next generation test in 2015.
  • Conference Call and Webcast
    Vermillion will hold a conference call to discuss its first quarter results later today, Wednesday, May 15, 2013 at 4:30 p.m. Eastern time. Vermillion's President and CEO Thomas McLain will host the call, followed by a question and answer period.

    Date: Wednesday, May 15, 2013
    Time: 4:30 p.m. Eastern time
    Dial-In number: 1-800-709-0218
    International: 1-212-231-2915
    Conference ID: 21656230
    Webcast: http://www.media-server.com/m/p/mo7xofgw

    The conference call will be webcast live and available for replay via the investor section of the company's website at www.vermillion.com.

    Please call the conference telephone number 5-10 minutes prior to the start time. An operator will regi
    '/>"/>

    SOURCE Vermillion, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Vermillion Sharpens Focus and Streamlines Operations in 2012
    2. Vermillion Reports Fourth Quarter and Full Year 2011 Results
    3. Vermillion Reports First Quarter 2012 Results
    4. Concerned Stockholders Launch Save Vermillion! Website: www.savevrml.com
    5. Vermillion to Participate in Lazard Capital Markets 5th Annual Medical Technology Snowbird Conference on February 27, 2013
    6. Vermillion to Report Results for Fourth Quarter and Full Year 2012 on Wednesday, February 20, 2013
    7. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
    8. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
    9. Interleukin Genetics Reports Third Quarter 2011 Financial Results
    10. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
    11. Nile Therapeutics Reports 2011 Third Quarter Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/31/2014)... 2014 This is a professional ... the Epoxy Hardener industry in Global and ... the industry, including definitions, applications and industry chain ... analysis are provided with a focus on history, ... A comparison between the international and Chinese situation ...
    (Date:8/29/2014)... (PRWEB) August 29, 2014 The ... $5.6 billion in 2019. It is expected to ... to 2019, and was valued at $1.8 billion ... by Transparency Market Research. , For more information ... http://www.transparencymarketresearch.com/companion-diagnostics-market.html . , The research report, titled “Companion ...
    (Date:8/29/2014)... Local veterinarian, Dr. Keith Clement, and his ... to participate in an investigational study of donor stem ... of this study is to determine if a single ... arthritically affected joints can help reduce pain and inflammation ... current investigational study must be older than nine months, ...
    (Date:8/29/2014)... Antonio, TX (PRWEB) August 29, 2014 ... and ISO 13485:2003 certified, GAMP® 5 compliant imaging ... awarded an international Phase II clinical trial to ... lymphoma. , Throughout this trial, Intrinsic Imaging will ... not limited to, protocol and charter development, site ...
    Breaking Biology Technology:Epoxy Hardener Industry Development Trends in Global & China Regions Now Available at ReportsnReports.com 2Epoxy Hardener Industry Development Trends in Global & China Regions Now Available at ReportsnReports.com 3Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 3Burnt Hills Veterinary Hospital Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2
    ... LLC, a clinical-stage drug development company commercializing first-in-class ... completion of a $2.9 million private placement. ... and clinical programs for its lead drug compound, ... David G. Kalergis, Chief Executive Officer of Diffusion ...
    ... 6 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical,Inc. ("China ... CSKI ), a leading,fully integrated pharmaceutical company ... ("PRC"), today announced that the Company,s,Chief Financial Officer, ... meetings at the upcoming Roth 21st Annual OC ...
    ... Tigris Pharmaceuticals, Inc., a privately held drug development ... Investigational New Drug (IND) application with the U.S. ... novel anticancer compound. GGTI-2418 is a synthetic ... appears to induce apoptosis by downregulating several pivotal ...
    Cached Biology Technology:Diffusion Pharmaceuticals Announces Completion of a $2.9 Million Private Placement and Company Presentations at Upcoming Industry Conferences in Geneva, Switzerland and Naples, Florida 2Diffusion Pharmaceuticals Announces Completion of a $2.9 Million Private Placement and Company Presentations at Upcoming Industry Conferences in Geneva, Switzerland and Naples, Florida 3China Sky One Medical, Inc. CFO to Present at Roth Conference 2China Sky One Medical, Inc. CFO to Present at Roth Conference 3Tigris Pharmaceuticals Files IND Application for GGTI-2418 2Tigris Pharmaceuticals Files IND Application for GGTI-2418 3
    (Date:8/29/2014)... of Texas Medical Branch at Galveston has gone on record ... protect monkeys against a lethal dose of Ebola virus up ... disease is severe. , Thomas Geisbert, professor of microbiology and ... advances in Ebola treatment research. The filoviruses known as Ebola ... pathogens, with fatality rates of up to 90 percent. ...
    (Date:8/29/2014)... researchers explored the type and number of connections in ... plays on robustness in a study published in ... found that the assortativity signature contributes to a network,s ... that varying the out-out assortativity of TFN models has ... the other three types of assortativity," said Dov A. ...
    (Date:8/29/2014)... This news release is available in German . ... of chemical signals between organisms is considered the oldest ... social interactions between conspecifics, for example, the sexual attraction ... trigger social responses and to coordinate reproductive behavior in ... at the University of the Algarve in Faro, Portugal, ...
    Breaking Biology News(10 mins):Leading Ebola researcher at UTMB says there's an effective treatment for Ebola 2Assortativity signatures of transcription factor networks contribute to robustness 2Ready for mating at the right time 2Ready for mating at the right time 3
    ... the observation that a large group of seemingly unconnected ... Now a multi-national research team led by the Melbourne ... has joined the proverbial dots and identified a potential ... paper published today in the prestigious Nature Medicine journal. ...
    ... (IAA), commonly referred to as auxin, plays a major ... development by affecting the expression of numerous genes that ... in specific plant tissues at specific stages during the ... floral organs to develop in the correct patterns and ...
    ... them the Dirt Doctors, or Sultans of Soil, they're just ... has a paper in this week's Science Magazine with a ... in the highly complex world beneath our feet. , "Computational ... Soil," by Jason Gans, Murray Wolinsky and John Dunbar, of ...
    Cached Biology News:Scientists find microRNAs regulate plant development 2Scientists find microRNAs regulate plant development 3Scientists find microRNAs regulate plant development 4Comparison of Cocaine, Methamphetamine ‘Highs?Finds Differences 2
    Schneider's Drosophila - Insect medium...
    ... and easy operation of a wide range ... The software is fully secure and compliant ... 11 regulations, and compatible with user-created macros ... enables use in high-level research and development ...
    ... is a proteohormone with a molecular weight of 16 ... ob gene and produced by adipocytes [1,2]. Leptin ... regulation of body weight [1-3]. In the human, ... men and women [4]. A relationship between serum ...
    ... Components in this kit are prepared ... technology. Biochains Mitochondria Isolation Kit is ... in a fast and easy way. One ... performing 100 isolations (enriching mitochondria from 10 ...
    Biology Products: